Pharmacokinetics

Pharmacokinetics asks how a substance reaches the body, where it goes and how it is removed over time. A receptor experiment cannot answer those questions on its own. Absorption, distribution, metabolism and elimination shape the exposure available to act. Half-life describes a decline in concentration; it is not a promise about benefit, safety or how long every effect lasts. [1] [2]

What you will learn

Explain absorption, distribution, metabolism and elimination in a concentration–time study.
Interpret half-life as a proportional decline during a specified phase.
Check the molecule, formulation, sampling compartment and population before comparing exposure estimates.

Start with the journey

Absorption is entry into the circulation from the place a substance is delivered. Distribution describes movement between blood and tissues. Metabolism changes its chemical form, and elimination removes the substance or its products from the body. Researchers often abbreviate these ideas as ADME. They are connected processes, so a low measured blood concentration can have more than one explanation. [2]

Bioavailability describes the fraction of a delivered substance that reaches the systemic circulation unchanged. Relative bioavailability compares exposure from one formulation with a reference under compatible conditions. A material in a cell dish is already in contact with the cells. In a person, barriers, degradation and distribution intervene. This is one reason a biological response in an assay does not specify the exposure that will occur in a human study. [1] [3]

Read the concentration curve

A concentration–time graph shows what was measured in a particular compartment, often plasma, the liquid part of blood. Its peak is one feature; the area under the curve, or AUC, combines concentration and time into an exposure measure. Two curves can have similar overall exposure and different peaks. The measurement site also matters: a plasma curve is not automatically a direct measurement inside every target tissue. [1]

Clearance describes the body's capacity to remove a substance from the measured circulation. Volume of distribution is an apparent volume connecting the amount in the body with the measured concentration; it is not necessarily a literal container of fluid. Together, distribution and clearance help explain the decline in concentration. A single half-life number summarizes part of that behavior and may conceal a more complex curve. [2]

What half-life does and does not mean

During a phase with exponential decline, one half-life corresponds to a halving of concentration. The next comparable interval halves what remains, rather than subtracting the same fixed amount. Biological effects need not stop at exactly that point. Effects also depend on the concentration at the target and the response being measured. Half-life is therefore a descriptive study property, not a stand-alone judgment that a substance works better. [1] [2]

A population analysis of semaglutide combined data from nine clinical pharmacology trials in healthy participants and people with type 2 diabetes. The investigators modeled absorption, distribution and elimination using measured concentrations. This is a specific kind of evidence: it describes exposure for a defined molecule in studied populations. It does not replace trials that measure clinical outcomes, and it does not authenticate another material carrying the same name. [4]

That analysis also illustrates why a model is useful. Several physiological spaces and processes can contribute to a curve, while the measurements come from finite sampling times. A compartment model organizes those observations and estimates properties under stated assumptions. Read the population, sampling and model description alongside the estimate. A precise-looking number still belongs to the material and participants used to generate it. [4]

The formulation is part of the question

Research on oral semaglutide investigated a tablet containing semaglutide together with an absorption enhancer. Clinical and preclinical observations supported stomach absorption tied to that coformulation. The point for readers is specific: an oral formulation's evidence belongs to that formulation. It does not show that swallowing any peptide with a similar name produces the same exposure, or that an enhancer works identically for every compound. [3]

Use this when reading a paper

Record the molecule, formulation, measurement site and population before comparing exposure estimates. Then ask which question the paper answers: how much material circulated, what signal changed, or what happened to people. Those questions can complement one another without being the same. Missing exposure information is an unanswered connection, rather than permission to assume that a cell result transfers unchanged. [4] [3]

Common questions

Is half-life the same as duration of benefit? No. Concentration decline and the duration of a measured effect are related questions, but they are not the same measurement. [1]

Does a high blood concentration prove effectiveness? It describes exposure. Effectiveness and harms require appropriate outcome measurements in the studied setting. [4]

Can two formulations be treated as identical? Only a relevant comparison can establish how their exposure relates. The name alone does not settle absorption or distribution. [3]

Worked example: follow a hypothetical half-life

This is a mathematical illustration, not measured peptide data. Assume that a substance’s concentration is 100 arbitrary units at the start of an elimination phase, declines exponentially and has a half-life of two hours. Assume no further input during this period. After two hours, the concentration is 50 arbitrary units; after four hours, it is 25; after six hours, it is 12.5. Each interval halves the current concentration rather than subtracting another 50 units. [1]

The calculation describes concentration under its assumptions. It does not specify an effective concentration, an amount to administer or how long a biological effect lasts. If the real curve also reflects continuing absorption or redistribution among tissues, the measured decline may need a more complex model. [1] [2]

Return to a real paper and ask what was measured, where and in whom. A plasma assay of intact peptide and a measurement of a breakdown product answer different questions. A modeled half-life becomes interpretable when those details and the fitted phase accompany the number. [1] [4]

Check your understanding

In the illustration, why is the concentration 25 arbitrary units after two half-lives rather than zero?

Show explanation

The second interval halves the concentration from 50 to 25 arbitrary units. Exponential decline is proportional to the current concentration, so two halvings leave one quarter of the starting concentration. [1]

An oral formulation produces measurable exposure. Does that establish the same absorption for the unformulated peptide?